Bipolar Disorder
Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases
by Joanna P. MacEwan, PhD; Seth Seabury, PhD; Myrlene Sanon
August 1, 2016
No Comments
by Joanna P. MacEwan, PhD; Seth Seabury, PhD; Myrlene Sanon
by Kimberly B. Mulcahy, PharmD; Eileen Trigoboff, RN, DNS; Lewis
by Masaru Nakamura, MD, PhD; Takahiko Nagamine, MD, PhD; Goro
by Cynthia A. Bossie, PhD; Larry D. Alphs, MD, PhD;
by Rocco Salvatore Calabrò, MD, PhD; Giuseppe Gervasi, MD, PhD;
by Ibrahim Turkoz, PhD; Dong-Jing Fu, MD, PhD; Cynthia A.
by Masaru Nakamura, MD, PhD, and Takahiko Nagamine, MD, PhD
Dear Editor: An estimated 75 million Americans experience nonmalignant chronic
by Irismar Reis de Oliveira, MD, PhD; Camila Seixas, PhD;
by Sriram Ramaswamy, MD; Vithyalakshmi Selvaraj, MBBS; David Driscoll, PhD; Jayakrishna
